All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-10-22T13:05:38.000Z

Gene expression profiling more sensitive than FISH for identifying double-hit DLBCL

Oct 22, 2019
Share:

Bookmark this article

Diffuse large B-cell lymphoma (DLBCL), the most common subtype of NHL, presents with a wide range of clinical characteristics and prognostic factors, depending on the underlying biology. The two major biologically distinct subgroups of DLBCL are germinal center B-cell-like (GCB) and activated B-cell-like (ABC), with the ABC subtype conferring a poorer prognosis.1 In addition to the ABC and GCB subtypes, the high-grade DLBCL can be divided by the presence or absence of rearrangements in genes encoding MYC and BCL2 and/or BCL6. Tumors with these genetic abnormalities are referred to as a double/triple hit (HGBL-DH/TH-BCL2) and are also associated with the worst outcomes.2,3 Therefore, the profiling of DLBCL tumors is crucial for stratifying patients’ risk and planning treatment that targets the underlining biology of different molecular subgroups.

A recent report showed that nearly 30% of GCB-DLBCL tumors have a gene expression pattern that resembles the double-hit signature (DHITsig). However, both MYC and BCL2 rearrangements could only be identified by standard break-apart fluorescence in situ hybridization (FISH), in half of the cases.4 Laura Hilton from Simon Fraser University, Burnaby, CA, and colleagues, published in Blood the results of a study that aimed to identify a more sensitive way to detect the double-hit biology underlying the poorer outcomes within GCB-DLBCL.5

Methods

Whole genome sequencing (WGS) was performed on DNA from the 20 fresh-frozen GCB tumors showing double-hit signature (DHITsig+) with no MYC and/or BCL2 translocations detected by break-apart FISH.4 Copy number variants (CNVs) analysis was also completed.

Main findings

Six HGBL-DH/TH tumors were identified by WGS (three cases of MYC rearrangement and three of BCL2) that were not detected by break-apart FISH. The results were confirmed by immunohistochemistry. WGS structural variant calling detected all BCL2 and MYC rearrangements identified by FISH. All cryptic MYC translocations had non-IG partner loci, while BCL2 translocations had IG partner.

Alterations in copy number affecting MYC and associated downstream pathways were found in several DHITsig+ tumors, including copy number gains affecting MIR17HG (6/20 cases). SNP array copy number profiles revealed enrichment in DHITsig+ tumors for amplifications of MIR17HG and FCGR2B, as well as deletions of CDKN2A and 22q11.22 (IGL). Additionally, the authors did not find an association between the 11q aberration and the DHITsig in DLBCL.

Conclusion

The data demonstrate the limitations of FISH in identifying HGBL-DH/TH, a high-risk GCB-DLBCL. Gene expression profiling was more sensitive for identifying double-hit biology. Moreover, the DHITsig+ was associated with various genetic events affecting MYC, BCL2, and their downstream pathways.

  1. Cho MC et al., Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP. Medicine (Baltimore). 2018 Nov;97(45):e13046. DOI: 10.1097/MD.0000000000013046
  2. Ennishi D et al., Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. Blood. 2017 May 18;129(20):2760-2770. DOI: 10.1182/blood-2016-11-747022
  3. Scott DW et al., High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood. 2018 May 3;131(18):2060-2064. DOI: 10.1182/blood-2017-12-820605
  4. Ennishi D et al., Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2019 Jan 20;37(3):190-201. DOI: 10.1200/JCO.18.01583
  5. Hilton LK et al., The double hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH. Blood. 2019 Sep 16. pii: blood.2019002600. DOI: 10.1182/blood.2019002600

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox